Skin Benign Neoplasm

Categories: Cancer diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Skin Benign Neoplasm

MalaCards integrated aliases for Skin Benign Neoplasm:

Name: Skin Benign Neoplasm 11 14
Neoplasm of Skin by Site 11
Benign Neoplasm of Skin 71
Tumor of the Skin 11
Skin Neoplasms 71
Skin Tumor 53


External Ids:

Disease Ontology 11 DOID:3165
MeSH 43 D012878
NCIt 49 C3372
SNOMED-CT 68 126488004
ICD10 31 D23.9
UMLS 71 C0004998 C0037286

Summaries for Skin Benign Neoplasm

MalaCards based summary: Skin Benign Neoplasm, also known as neoplasm of skin by site, is related to malignant syringoma and skin papilloma, and has symptoms including pruritus and exanthema. An important gene associated with Skin Benign Neoplasm is KRT14 (Keratin 14), and among its related pathways/superpathways are Breast cancer pathway and G-Beta Gamma Signaling. The drugs Etanercept and Sirolimus have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and t cells, and related phenotypes are homeostasis/metabolism and growth/size/body region

Related Diseases for Skin Benign Neoplasm

Diseases related to Skin Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 447)
# Related Disease Score Top Affiliating Genes
1 malignant syringoma 32.0 KRT5 KRT20
2 skin papilloma 32.0 STAT3 ODC1 KRT14 KRT1 HRAS
3 cowden syndrome 1 31.7 MSH6 MSH2 MLH1 HRAS FLCN
4 mixed cell type cancer 31.5 SERPINA3 MLH1 KRT5 HRAS
5 papilloma 31.0 TP63 ODC1 KRT5 KRT20 KRT14 KRT1
6 skin carcinoma 30.8 XPA PTCH1 ODC1 MSH2 KRT5 KRT20
7 muir-torre syndrome 30.6 MSH6 MSH2 MLH1 KRT5 HRAS
8 keratoacanthoma 30.5 TP63 STAT3 MSH2 MLH1 KRT14
9 keratosis 30.4 KRT5 KRT14 KRT1 HRAS FGFR3
10 actinic keratosis 30.4 XPA TP63 KRT14
11 xeroderma pigmentosum, variant type 30.3 XPA PTCH1 MSH6 MSH2 MLH1
12 meningioma, familial 30.3 SERPINA3 PTCH1 ODC1 HRAS GLI2 GLI1
13 neurofibromatosis 30.3 MSH6 MSH2 MLH1 HRAS BRAF
14 polycystic liver disease 1 with or without kidney cysts 30.3 PTCH1 KRT20 FLCN
15 neurofibromatosis, type i 30.2 MSH6 MSH2 MLH1 HRAS
16 skin squamous cell carcinoma 30.2 MSH6 MSH2 MLH1 KRT5 KRT14 HRAS
17 epithelial-myoepithelial carcinoma 30.1 KRT5 KRT14
18 cutaneous leiomyosarcoma 30.1 KRT5 FLCN
19 dysplastic nevus syndrome 30.1 MSH6 MSH2 MLH1
20 melanoma, cutaneous malignant 1 30.1 MSH6 MSH2 MLH1 HRAS BRAF
21 adenoma 30.0 MSH6 MSH2 MLH1 KRT20 HRAS BRAF
22 sebaceous adenocarcinoma 30.0 MSH6 MSH2 MLH1 KRT5 KRT14
23 squamous cell carcinoma 29.9 TP63 STAT3 KRT14 HRAS FGFR3 BRAF
24 sebaceous adenoma 29.9 SERPINA3 MSH6 MSH2 MLH1 KRT14
25 basal cell nevus syndrome 29.9 PTCH1 HRAS GLI2 GLI1
26 epithelioid sarcoma 29.8 TP63 SERPINA3 KRT20 KRT14 KRT1
27 basal cell carcinoma 29.8 XPA TP63 STAT3 PTCH1 MSH2 MLH1
28 adenoid cystic carcinoma 29.8 TP63 SERPINA3 KRT20 KRT14 HRAS
29 cowden syndrome 29.8 PTCH1 MSH6 MSH2 MLH1 HRAS FLCN
30 wilms tumor 1 29.8 SERPINA3 KRT5 HRAS BRAF
31 lynch syndrome 29.8 XPA MSH6 MSH2 MLH1 HRAS BRAF
32 familial adenomatous polyposis 29.8 ODC1 MSH6 MSH2 MLH1 HRAS BRAF
33 intestinal benign neoplasm 29.8 STAT3 SERPINA3 MSH6 MSH2 MLH1 HRAS
34 skin disease 29.7 TP63 STAT3 SERPINA3 PTCH1 KRT5 KRT14
35 brain cancer 29.7 STAT3 PTCH1 MSH6 MSH2 GLI1 BRAF
36 colonic benign neoplasm 29.6 STAT3 SERPINA3 ODC1 MSH6 MSH2 MLH1
37 squamous cell carcinoma, head and neck 29.6 TP63 STAT3 MLH1 HRAS FGFR3 BRAF
38 lung cancer susceptibility 3 29.5 TP63 STAT3 MLH1 KRT20 HRAS FGFR3
39 bladder cancer 29.3 TP63 STAT3 PTCH1 MSH2 MLH1 KRT20
40 pancreatic cancer 29.2 STAT3 SERPINA3 PTCH1 MSH6 MSH2 MLH1
41 breast cancer 29.1 TP63 STAT3 SERPINA3 ODC1 MSH6 MSH2
42 skin lipoma 11.1
43 malignant granular cell skin tumor 11.0
44 genetic skin tumor or hamartoma 11.0
45 rare skin tumor or hamartoma 11.0
46 keratosis, seborrheic 10.9
47 birt-hogg-dube syndrome 10.9
48 brooke-spiegler syndrome 10.9
49 paget disease, extramammary 10.8
50 discoid fibromas, familial multiple 10.8

Graphical network of the top 20 diseases related to Skin Benign Neoplasm:

Diseases related to Skin Benign Neoplasm

Symptoms & Phenotypes for Skin Benign Neoplasm

UMLS symptoms related to Skin Benign Neoplasm:

pruritus; exanthema

GenomeRNAi Phenotypes related to Skin Benign Neoplasm according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.2 BRAF FGFR3 FLCN GLA GLI1 GLI2
2 no effect GR00402-S-2 10.2 BRAF FGFR3 FLCN GLA GLI1 GLI2

MGI Mouse Phenotypes related to Skin Benign Neoplasm:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.41 BRAF FGFR3 FLCN GLA GLI2 HRAS
2 growth/size/body region MP:0005378 10.4 BRAF FGFR3 FLCN GLA GLI1 GLI2
3 neoplasm MP:0002006 10.38 BRAF FGFR3 FLCN GLI1 HRAS KRT14
4 cellular MP:0005384 10.28 BRAF FGFR3 FLCN GLA GLI1 GLI2
5 immune system MP:0005387 10.24 BRAF FGFR3 FLCN GLA KRT1 KRT14
6 digestive/alimentary MP:0005381 10.23 BRAF FGFR3 GLI1 GLI2 HRAS KRT14
7 normal MP:0002873 10.21 BRAF FGFR3 GLI1 GLI2 HRAS ODC1
8 renal/urinary system MP:0005367 10.2 BRAF FGFR3 FLCN GLA GLI1 HRAS
9 endocrine/exocrine gland MP:0005379 10.18 BRAF GLI1 GLI2 HRAS KRT14 MLH1
10 craniofacial MP:0005382 10.17 BRAF FGFR3 GLI1 GLI2 HRAS KRT14
11 muscle MP:0005369 10.14 BRAF GLA GLI2 HRAS PTCH1 STAT3
12 limbs/digits/tail MP:0005371 10.13 BRAF FGFR3 GLI1 GLI2 KRT5 PTCH1
13 respiratory system MP:0005388 10.06 BRAF FGFR3 GLI1 GLI2 HRAS KRT14
14 reproductive system MP:0005389 9.96 BRAF FGFR3 GLI1 GLI2 KRT14 MLH1
15 hematopoietic system MP:0005397 9.93 BRAF FGFR3 FLCN KRT1 KRT14 MLH1
16 mortality/aging MP:0010768 9.91 BRAF FGFR3 FLCN GLA GLI1 GLI2
17 integument MP:0010771 9.5 BRAF FGFR3 GLI2 HRAS KRT1 KRT14

Drugs & Therapeutics for Skin Benign Neoplasm

Drugs for Skin Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 328)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Etanercept Approved, Investigational Phase 4 185243-69-0
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
Azathioprine Approved Phase 4 446-86-6 2265
Mycophenolic acid Approved, Investigational Phase 4 24280-93-1 446541
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
9 Anti-Inflammatory Agents, Non-Steroidal Phase 4
10 Tin Fluorides Phase 4
11 Anti-Infective Agents Phase 4
12 Antimetabolites Phase 4
13 Immunosuppressive Agents Phase 4
14 Immunologic Factors Phase 4
15 Neurotransmitter Agents Phase 4
16 Dermatologic Agents Phase 4
17 Anti-Bacterial Agents Phase 4
18 Calcineurin Inhibitors Phase 4
19 Cyclosporins Phase 4
20 Antifungal Agents Phase 4
21 Antibiotics, Antitubercular Phase 4
22 Agglutinins Phase 4
abobotulinumtoxinA Phase 4
24 Botulinum Toxins, Type A Phase 4
25 Botulinum Toxins Phase 4
26 Hemagglutinins Phase 4
27 Cholinergic Agents Phase 4
Eflornithine Approved, Withdrawn Phase 3 70052-12-9 3009
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
Acetaminophen Approved Phase 3 103-90-2 1983
Nivolumab Approved Phase 3 946414-94-4
Dimethyl sulfoxide Approved, Vet_approved Phase 3 67-68-5 679
Trametinib Approved Phase 3 871700-17-3 11707110
Dabrafenib Approved, Investigational Phase 3 1195765-45-7 44462760
Ipilimumab Approved Phase 3 477202-00-9
Talimogene laherparepvec Approved, Experimental, Investigational Phase 3 1187560-31-1
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
Dacarbazine Approved, Investigational Phase 3 4342-03-4 2942 5351166
Ornithine Approved, Nutraceutical Phase 3 3184-13-2, 70-26-8 6262
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 3 67-97-0, 1406-16-2 5280795 10883523
42 Sunscreening Agents Phase 2, Phase 3
43 Methyl 5-aminolevulinate Phase 3
44 Monatide (IMS 3015) Phase 3
45 Freund's Adjuvant Phase 3
46 Radiation-Protective Agents Phase 2, Phase 3
47 Antipyretics Phase 3
48 Vitamins Phase 3
49 Trace Elements Phase 3
50 Antioxidants Phase 3

Interventional clinical trials:

(show top 50) (show all 501)
# Name Status NCT ID Phase Drugs
1 Efficacy of Rapamycin (Sirolimus) in the Treatment of Blue Rubber Bleb Nevus Syndrome, Hereditary or Sporadic Venous Malformation Unknown status NCT03767660 Phase 4 Rapamycin
2 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
3 A Randomized, Open-Label Study to Compare the Rate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolimus-based Regimen Versus Continuation of a Calcineurin Inhibitor-based Regimen Completed NCT00129961 Phase 4 sirolimus;cyclosporine or tacrolimus
4 Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients Completed NCT00492895 Phase 4 Discontinuation of Azathioprin
5 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
6 Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma: a Single Arm Prospective Study Recruiting NCT04056962 Phase 4 Tacrolimus ointment
7 Safety and Efficacy of Photodynamic Therapy With Aminolevulinic Acid 10% Topical Gel Activated by Red Light Versus Aminolevulinic Acid 20% Topical Solution Activated by Blue Light for the Treatment of Actinic Keratosis on the Upper Extremities: A Blinded Randomized Study Not yet recruiting NCT05359419 Phase 4
8 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
9 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
10 A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of AbobotulinumtoxinA (BTX-A) in Improving Forehead Wounds After Mohs Micrographic Surgery and Reconstruction for Skin Cancer Terminated NCT01459666 Phase 4 Dysport (abobotulinumtoxinA);Bacteriostatic 0.9% Sodium Chloride (vehicle)
11 CERTICOEUR a Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. An Open Labelled Randomized Everolimus vs Calcineurin Inhibitors Multicenter Trial Unknown status NCT00799188 Phase 3 Everolimus
12 CSP #402 - VA Topical Tretinoin Chemoprevention Trial Completed NCT00007631 Phase 3 Tretinoin 0.1% cream or placebo
13 Prospective and Randomized Study to Evaluate Interest of Ultracision Use in Inguinal Lymph Nodes Curage. Completed NCT00224744 Phase 3
14 A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With "No Evidence of Disease" After Complete Surgical Resection of "Locally Advanced" and/or Stage IV Melanoma Completed NCT01989572 Phase 3
15 A Multicentre, Randomised Study of Photodynamic Therapy(PDT) With Metvix® 160 mg/g Cream in Immuno-compromised Patients With Non-melanoma Skin Cancer Completed NCT00472459 Phase 3
16 Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients - Multicentric Randomized, Open-label Study of Rapamycin vs Calcineurin Inhibitors Completed NCT00133887 Phase 3 rapamycin;ciclosporine;tacrolimus
17 A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma Completed NCT00066872 Phase 3 imiquimod
18 A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma Completed NCT00110019 Phase 3 Carboplatin;Paclitaxel;Sorafenib Tosylate
19 Chemoprevention of Skin Cancers With DFMO: A Controlled, Randomized Clinical Trial Completed NCT00005884 Phase 3 eflornithine
20 Impact of Preoperative Acetaminophen and Carbohydrate Loading to on Pain and Functional Status in Patients Undergoing Mohs Micrographic Surgery for Non-melanoma Skin Cancers Completed NCT03131713 Phase 3 Acetaminophen
21 Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy in High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck Completed NCT00193895 Phase 3 Carboplatin
22 Prospective Study To Determine Whether Tissue Scoring Results In Noticeable Marks Following Mohs Micrographic Surgery Completed NCT00367042 Phase 2, Phase 3
23 A Phase III Multi-Institutional Randomized Study of Immunization With the gp100: 209-217 (210M) Peptide Followed by High Dose IL-2 vs. High Dose IL-2 Alone in Patients With Metastatic Melanoma Completed NCT00019682 Phase 3 Montanide ISA 51 VG
24 A Randomized Control Trial of Sun Protection Interventions for Operating Engineers Completed NCT01804595 Phase 2, Phase 3
25 Sun Safe Partners Online: Pilot Randomized Controlled Clinical Trial Completed NCT04549675 Phase 3
26 Melanoma Margins Trial-II - A Phase III, Multi-centre Randomised Controlled Trial Investigating 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma (02.18 MelMarT-II) Recruiting NCT03860883 Phase 3
27 A Personalized Approach to Skin Cancer Prevention Among Adolescents Recruiting NCT04341064 Phase 3
28 Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma Recruiting NCT02339571 Phase 2, Phase 3
29 A Phase III, Multi-centre, Multi-national Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma Active, not recruiting NCT02385214 Phase 3
30 A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma Active, not recruiting NCT02506153 Phase 3
31 DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial Active, not recruiting NCT02224781 Phase 3 Dabrafenib Mesylate;Trametinib Dimethyl Sulfoxide
32 A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High Risk Melanoma Active, not recruiting NCT01274338 Phase 3
33 Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome Active, not recruiting NCT01748448 Phase 3 Vitamin D;arachides oleum raffinatum
34 Risk Information and Skin-Cancer Education and Undergraduate Prevention Trial Not yet recruiting NCT05634252 Phase 3
35 Prophylactic LYMphatic Reconstruction (LYMbR) to Prevent Lymphedema Not yet recruiting NCT05136079 Phase 3
36 PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma Terminated NCT02288897 Phase 3 PV-10 (10% rose bengal disodium);Dacarbazine, temozolomide or talimogene laherparepvec
37 HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma Unknown status NCT02836548 Phase 1, Phase 2 Vorinostat
38 Investigation of the Effectiveness of Non-Coherent Blue Light in Intralesional Photodynamic of Basal Cell Carcinoma Unknown status NCT00747903 Phase 2 aminolevulinic acid hydrochloride
39 A Phase I/II Pilot Study of Bioimmunotherapy With IRESSA (Gefitinib) and Pegylated Interferon Alpha-2a for Patients With Unresectable/Metastatic Squamous Cell Carcinoma of the Skin Unknown status NCT00423397 Phase 1, Phase 2 gefitinib
40 Skin Cancer Prophylaxis by Low-Fat Dietary Intervention Unknown status NCT00003097 Phase 2
41 A Phase 2, Open-Label Evaluation of the Safety and Efficacy of CB-10-01, Transgenic Lymphocyte Immunization (TLI) Against Telomerase, as Adjuvant Therapy in Subjects With Stage III Melanoma Unknown status NCT00925314 Phase 2
42 Immunotherapy Followed By EGFR Inhibitor In Locally Advanced Or Metastatic Squamous Cell Cancer Of The Skin: Tackling Primary And Secondary Resistance Unknown status NCT03666325 Phase 2 Pembrolizumab;Cetuximab
43 Transient Infrared Imaging for Early Detection of Skin Cancer Unknown status NCT02154451 Phase 1, Phase 2
44 Phase IIB Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine and Topical Diclofenac in the Treatment of Sun-Damaged Skin on the Forearm Completed NCT00601640 Phase 2 Diclofenac Na gel;Eflornithine HCL ointment
45 A Prospective, Randomized, Double-blinded Comparison of the Use of 5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts. Completed NCT02705352 Phase 2 5-Fluorouracil
46 Phase II Trial of Gleevec (Imatinib Mesylate, STI-571) in Metastatic Melanoma Completed NCT00027586 Phase 2 Imatinib mesylate (STI571)
47 Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma Completed NCT00094107 Phase 2 Axitinib [AG-013736]
48 Phase 2b Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients (OTR) Completed NCT00204789 Phase 2 Difluoromethylornithine
49 A Phase II Pilot Trial of an Indoleamine 2,3, Dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients With Advanced Melanoma Completed NCT01961115 Phase 2 Epacadostat
50 A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma Completed NCT00804908 Phase 2 temozolomide;ABT-888

Search NIH Clinical Center for Skin Benign Neoplasm

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Interferon Alfa-2a
Interferon Alfa-2b
interferon alfacon-1
Interferon gamma-1b
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b

Genetic Tests for Skin Benign Neoplasm

Anatomical Context for Skin Benign Neoplasm

Organs/tissues related to Skin Benign Neoplasm:

MalaCards : Skin, Lymph Node, T Cells, Brain, Liver, Lung, Breast

Publications for Skin Benign Neoplasm

Articles related to Skin Benign Neoplasm:

(show top 50) (show all 3087)
# Title Authors PMID Year
A positive FGFR3/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans. 53 62
19729838 2009
The human promyelocytic leukemia protein is a tumor suppressor for murine skin carcinogenesis. 53 62
19058256 2009
p38delta Mitogen-activated protein kinase is essential for skin tumor development in mice. 53 62
19458068 2009
Stage-specific disruption of Stat3 demonstrates a direct requirement during both the initiation and promotion stages of mouse skin tumorigenesis. 53 62
18453544 2008
Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas. 53 62
16826164 2006
Plasminogen activators and their inhibitor gene expression in cutaneous NF1-related neurofibromas. 53 62
16408192 2006
Role of PI3K/Akt signaling in insulin-like growth factor-1 (IGF-1) skin tumor promotion. 53 62
16086373 2005
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. 53 62
15772091 2005
Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. 53 62
15343391 2004
Stat3 is required for the development of skin cancer. 53 62
15343379 2004
In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. 53 62
15141228 2004
Loss of tyrosinase activity confers increased skin tumor susceptibility in mice. 53 62
15007389 2004
E2F modulates keratinocyte squamous differentiation: implications for E2F inhibition in squamous cell carcinoma. 53 62
12754218 2003
Retinoids in chemoprevention of cancer. 53 62
12757023 2003
Inhibitory effect of glycolic acid on ultraviolet B-induced c-fos expression, AP-1 activation and p53-p21 response in a human keratinocyte cell line. 53 62
12213282 2002
Dissecting the oncogenic potential of Gli2: deletion of an NH(2)-terminal fragment alters skin tumor phenotype. 53 62
12235001 2002
Overexpression of a constitutively active form of c-src in skin epidermis increases sensitivity to tumor promotion by 12-O-tetradecanoylphorbol-13-acetate. 53 62
11870880 2002
Inhibition of mouse skin tumor promotion by anti-inflammatory diarylheptanoids derived from Alpinia oxyphylla Miquel (Zingiberaceae). 53 62
12201673 2002
The neurofibromatosis type 1 (Nf1) tumor suppressor is a modifier of carcinogen-induced pigmentation and papilloma formation in C57BL/6 mice. 53 62
10844550 2000
Enhancement of susceptibility to diverse skin tumor promoters by activation of the insulin-like growth factor-1 receptor in the epidermis of transgenic mice. 53 62
10365914 1999
12-lipoxygenase expression in human melanoma cell lines. 53 62
10667390 1999
Transforming activity of the chimeric sequence formed by the fusion of collagen gene COL1A1 and the platelet derived growth factor b-chain gene in dermatofibrosarcoma protuberans. 53 62
9771975 1998
Differential activation of mitogen-activated protein kinases by palytoxin and ouabain, two ligands for the Na+,K+-ATPase. 53 62
9707514 1998
Competent transcription initiation by RNA polymerase II in cell-free extracts from xeroderma pigmentosum groups B and D in an optimized RNA transcription assay. 53 62
9427533 1997
E2F as a regulator of keratinocyte proliferation: implications for skin tumor development. 53 62
9242506 1997
The DNA repair protein O6-methylguanine-DNA methyltransferase protects against skin tumor formation induced by antineoplastic chloroethylnitrosourea. 53 62
9269990 1997
Inhibition of tumor promotion in SENCAR mouse skin by ethanol extract of Zingiber officinale rhizome. 53 62
8640756 1996
Recombinagenic activity of the phorbol ester 12-O-tetradecanoylphorbol-13-acetate in human lymphoblastoid cells. 53 62
7634395 1995
Low frequency of codon 61 Ha-ras mutations and lack of keratin 13 expression in 7,12-dimethylbenz[a]-anthracene-induced hamster skin tumors. 53 62
7681292 1993
Periocular Merkel Cell Carcinoma - An Overview of Clinical Aspects and Current Treatment Options. 62
36368663 2022
[Correlation between Connexin 43 Mutation and Skin Diseases]. 62
36373638 2022
Cholecystokinin Receptor Antagonist Suppresses Melanoma Growth by Inducing Apoptosis of Tumor Cells. 62
36262666 2022
Delay in Seeking Medical Attention and Diagnosis in Chinese Melanoma Patients: A Cross-Sectional Study. 62
36429635 2022
PARP1 Is a Prognostic Marker and Targets NFATc2 to Promote Carcinogenesis in Melanoma. 62
36394458 2022
Identification and Validation of a Novel Model: Predicting Short-Term Complications After Local Flap Surgery for Skin Tumor Removal. 62
36384866 2022
Multiple Pyogenic Granulomas in the External Auditory Canal. 62
36433695 2022
Characterization and dynamics of the soluble immunological microenvironment in melanoma patients undergoing radiotherapy. 62
36443849 2022
Lipomatous mixed tumor of the skin with cystic formation affecting the upper lip: A case report. 62
36168412 2022
hsa_circ_0038382 upregulates T-box transcription factor 5 to inhibit keloid formation by interacting with miR-940. 62
36413177 2022
Surgical experiences in pediatric pilomatricoma: punch incision and elliptical excision. 62
36214494 2022
Giant pilomatrixoma with bullous appearance on the back: A case report and discussion of misdiagnosis. 62
35332644 2022
Human papillomavirus 42 drives digital papillary adenocarcinoma and elicits a germ-cell like program conserved in HPV-positive cancers. 62
36213965 2022
Combination of Optical Biopsy with Patient Data for Improvement of Skin Tumor Identification. 62
36292192 2022
Reconstruction of Head and Neck Region with Supraclavicular Artery Flap. 62
36452613 2022
Usefulness of ultrasonography in the preoperative diagnosis of mixed tumor of the skin (chondroid syringoma): A case series with nine patients. 62
35718945 2022
Skin endothelial cell and microcirculation function study in recurred keloids patients after keloid surgery and radiotherapy. 62
36316928 2022
Mutant Ras and inflammation-driven skin tumorigenesis is suppressed via a JNK-iASPP-AP1 axis. 62
36261000 2022
The Use of Matriderm® for Scalp Full-Thickness Defects Reconstruction: A Case Series. 62
36294362 2022
[Clinical effects of lateral supramalleolar perforator island flaps with low rotation points in repairing foot skin and soft tissue defect wounds]. 62
36299204 2022
Tumor Doubling Time in Skin Cancer: Can It Be Estimated and Is it Useful? 62
36273551 2022

Variations for Skin Benign Neoplasm

Expression for Skin Benign Neoplasm

Search GEO for disease gene expression data for Skin Benign Neoplasm.

Pathways for Skin Benign Neoplasm

Pathways directly related to Skin Benign Neoplasm:

# Pathway Source
1 Defective CYP26C1 causes FFDD4 Reactome 66

Pathways related to Skin Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
3 12.27 XPA TP63 MSH6 MSH2 MLH1
Show member pathways
6 11.75 KRT14 KRT1 BRAF
7 11.68 XPA MSH2 MLH1
8 11.62 TP63 HRAS FGFR3
10 11.51 STAT3 HRAS BRAF
11 11.41 KRT14 KRT5 TP63
Show member pathways
11.38 STAT3 MSH2 MLH1
13 11.35 HRAS FGFR3 BRAF
14 11.32 PTCH1 GLI2 GLI1
15 11.29 HRAS FGFR3 BRAF
16 11.26 PTCH1 GLI2 GLI1
17 11.23 BRAF HRAS STAT3
18 11.21 GLI1 GLI2 PTCH1
Show member pathways
11.14 PTCH1 GLI2 GLI1
20 11.02 STAT3 GLI2 GLI1
21 10.9 PTCH1 GLI2 GLI1
22 10.64 PTCH1 GLI1
23 10.39 XPA MSH6 MSH2 MLH1

GO Terms for Skin Benign Neoplasm

Cellular components related to Skin Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mismatch repair complex GO:0032300 9.33 MSH2 MLH1
2 GLI-SUFU complex GO:1990788 9.13 GLI2 GLI1
3 MutSalpha complex GO:0032301 8.92 MSH6 MSH2

Biological processes related to Skin Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell population proliferation GO:0008284 10.33 TP63 ODC1 HRAS GLI2 GLI1 FGFR3
2 animal organ morphogenesis GO:0009887 10.16 TP63 PTCH1 HRAS BRAF
3 stem cell proliferation GO:0072089 10.02 TP63 PTCH1 GLI2
4 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 10.01 MSH6 MSH2 MLH1
5 intrinsic apoptotic signaling pathway GO:0097193 9.99 FLCN HRAS MSH6
6 dorsal/ventral pattern formation GO:0009953 9.98 PTCH1 GLI2 GLI1
7 epidermis development GO:0008544 9.97 TP63 PTCH1 KRT5 KRT14
8 mismatch repair GO:0006298 9.95 MSH6 MSH2 MLH1
9 pattern specification process GO:0007389 9.91 TP63 PTCH1 GLI2
10 proximal/distal pattern formation GO:0009954 9.91 TP63 GLI2 GLI1
11 positive regulation of helicase activity GO:0051096 9.9 MSH2 MSH6
12 isotype switching GO:0045190 9.88 MLH1 MSH2 MSH6
13 positive regulation of isotype switching to IgA isotypes GO:0048298 9.86 MSH2 MLH1
14 intermediate filament organization GO:0045109 9.86 KRT5 KRT20 KRT14 KRT1
15 cerebellar cortex morphogenesis GO:0021696 9.84 GLI2 GLI1
16 mammary gland duct morphogenesis GO:0060603 9.77 GLI2 PTCH1
17 ventral midline development GO:0007418 9.76 GLI2 GLI1
18 negative regulation of hh target transcription factor activity GO:1990787 9.75 GLI2 GLI1
19 prostatic bud formation GO:0060513 9.74 TP63 GLI2
20 maintenance of DNA repeat elements GO:0043570 9.72 MSH6 MSH2
21 smoothened signaling pathway involved in regulation of cerebellar granule cell precursor cell proliferation GO:0021938 9.7 GLI2 GLI1
22 somatic hypermutation of immunoglobulin genes GO:0016446 9.63 MSH6 MSH2 MLH1
23 notochord regression GO:0060032 9.54 GLI2 GLI1
24 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.5 MSH2 MLH1
25 prostate gland development GO:0030850 9.35 TP63 PTCH1 GLI1
26 somatic recombination of immunoglobulin gene segments GO:0016447 9.02 MSH6 MSH2 MLH1

Molecular functions related to Skin Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 10.14 TP63 MSH6 MSH2 MLH1 GLI2 GLI1
2 MutLalpha complex binding GO:0032405 9.76 MSH6 MSH2
3 oxidized purine DNA binding GO:0032357 9.73 MSH6 MSH2
4 ATP-dependent DNA damage sensor activity GO:0140664 9.73 MSH6 MSH2 MLH1
5 single guanine insertion binding GO:0032142 9.67 MSH6 MSH2
6 damaged DNA binding GO:0003684 9.63 XPA TP63 MSH6 MSH2
7 single thymine insertion binding GO:0032143 9.62 MSH2 MSH6
8 mismatched DNA binding GO:0030983 9.35 MSH6 MSH2 MLH1
9 guanine/thymine mispair binding GO:0032137 9.1 MSH6 MSH2 MLH1

Sources for Skin Benign Neoplasm

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....